Purple Biotech (PPBT) Total Liabilities (2014 - 2026)
Purple Biotech (PPBT) posted quarterly Total Liabilities of $14.4 million for Q1 2026, down 59.5% year-over-year from $35.6 million in Q1 2025, and down 17.95% quarter-over-quarter from $17.6 million in Q4 2025.
Purple Biotech (PPBT) Total Liabilities (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Total Liabilities for 13 consecutive years, with $14.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 59.5% year-over-year to $14.4 million; the TTM figure through Mar 2026 stood at $14.4 million (down 59.5% YoY), while the FY2025 annual figure was $17.6 million, down 52.56% from the prior year.
- Total Liabilities retreated to $14.4 million in Q1 2026 per PPBT's latest filing, from $17.6 million in the prior quarter.
- Across five years, Total Liabilities topped out at $66.3 million in Q1 2022 and bottomed at $14.4 million in Q1 2026.
- Historically, Total Liabilities has averaged $42.4 million across 5 years, with a median of $39.9 million in 2024.
- Annual changes were most pronounced in 2025 — Total Liabilities gained 11.27% — and 2026, when it tumbled 59.5%.
- Purple Biotech's Total Liabilities stood at $54.6 million in 2022, then decreased by 18.89% to $44.3 million in 2023, then retreated by 16.4% to $37.0 million in 2024, then slumped by 52.56% to $17.6 million in 2025, then fell by 17.95% to $14.4 million in 2026.
- Business Quant data shows PPBT's Total Liabilities at $14.4 million in Q1 2026, $17.6 million in Q4 2025, and $39.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Purple Biotech | 133.62 | 133.62 | - | 14.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.42 Mn |
| Dec 31, 2025 | 17.57 Mn |
| Sep 30, 2025 | 39.06 Mn |
| Jun 30, 2025 | 34.38 Mn |
| Mar 31, 2025 | 35.59 Mn |
| Dec 31, 2024 | 37.04 Mn |
| Sep 30, 2024 | 35.11 Mn |
| Jun 30, 2024 | 36.07 Mn |
| Mar 31, 2024 | 39.86 Mn |
| Dec 31, 2023 | 44.30 Mn |
| Sep 30, 2023 | 45.27 Mn |
| Jun 30, 2023 | 48.00 Mn |
| Mar 31, 2023 | 53.08 Mn |
| Dec 31, 2022 | 54.62 Mn |
| Sep 30, 2022 | 58.54 Mn |
| Jun 30, 2022 | 61.74 Mn |
| Mar 31, 2022 | 66.29 Mn |
| Dec 31, 2021 | 70.20 Mn |
| Sep 30, 2021 | 73.63 Mn |
| Jun 30, 2021 | 76.49 Mn |